The Clinical Research of Mesylate Apatinib Combined With Docetaxel & S-1

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04618809` - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer	N/A
Recruiting	`NCT02668380` - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer	N/A
Completed	`NCT03121807` - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer	N/A
Recruiting	`NCT04358354` - Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer	Phase 3
Completed	`NCT01099527` - A Trial of RAD001/Capecitabine in Refractory Gastric Cancer	Phase 1/Phase 2
Completed	`NCT00253370` - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer	Phase 2
Recruiting	`NCT02002195` - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting	`NCT06008925` - Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer	Phase 1/Phase 2
Recruiting	`NCT05714124` - Liver Embolization Approaches for Tumor Management
Recruiting	`NCT02855788` - Metronomic Chemotherapy in Advanced Gastric Cancer	Phase 2
Not yet recruiting	`NCT04263870` - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction	Phase 2
Active, not recruiting	`NCT01359397` - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT04739202` - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)	Phase 2
Completed	`NCT03409848` - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma	Phase 2
Recruiting	`NCT05859477` - Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT05955833` - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study	Phase 1
Terminated	`NCT01528501` - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)	Phase 2
Completed	`NCT03751761` - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study	Phase 1/Phase 2
Recruiting	`NCT05024812` - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT03614013` - Resistance to Immunotherapy in Gastric Cancer

NCT number	NCT03154983
Study type	Interventional
Source	Zhongnan Hospital
Contact	Ling Xia, M.D.
Phone	18971250716
Email	82425583@qq.com
Status	Recruiting
Phase	Phase 2
Start date	May 20, 2017
Completion date	December 31, 2021

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms